BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36779660)

  • 1. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma.
    Planas-Paz L; Pliego-Mendieta A; Hagedorn C; Aguilera-Garcia D; Haberecker M; Arnold F; Herzog M; Bankel L; Guggenberger R; Steiner S; Chen Y; Kahraman A; Zoche M; Rubin MA; Moch H; Britschgi C; Pauli C
    EMBO Mol Med; 2023 Apr; 15(4):e16863. PubMed ID: 36779660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 3. Leveraging homologous recombination repair deficiency in sarcoma.
    Slade D; Loizou JI
    EMBO Mol Med; 2023 Apr; 15(4):e17453. PubMed ID: 36929572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
    Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    Pfarr N; Merkelbach-Bruse S
    Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
    Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
    Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
    Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
    Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
    Ding JH; Xiao Y; Yang F; Song XQ; Xu Y; Ding XH; Ding R; Shao ZM; Di GH; Jiang YZ
    Sci Transl Med; 2024 Jan; 16(728):eadg7740. PubMed ID: 38170790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
    Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
    Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
    Stewart MD; Merino Vega D; Arend RC; Baden JF; Barbash O; Beaubier N; Collins G; French T; Ghahramani N; Hinson P; Jelinic P; Marton MJ; McGregor K; Parsons J; Ramamurthy L; Sausen M; Sokol ES; Stenzinger A; Stires H; Timms KM; Turco D; Wang I; Williams JA; Wong-Ho E; Allen J
    Oncologist; 2022 Mar; 27(3):167-174. PubMed ID: 35274707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.
    Krumm N; Khasnavis NS; Radke M; Banda K; Davies HR; Pennil C; McLean K; Paulson VA; Konnick EQ; Johnson WC; Huff G; Nik-Zainal S; Swisher EM; Lockwood CM; Salipante SJ
    JCO Precis Oncol; 2023 May; 7():e2200720. PubMed ID: 37196218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.